Homology Medicines, Inc. Announces Promotion of Tim Kelly to Chief Operating Officer
April 12, 2021 at 01:30 pm
Homology Medicines, Inc. announced that Tim Kelly has been promoted to Chief Operating Officer, effective immediately. Previously, Mr. Kelly held the role of Chief Technical Operations Officer and led the construction of the Company's internal 25,000-square-foot GMP manufacturing facility, which was completed in 12 months from design to operation. As one of the first companies to scale to a 2,000-liter bioreactor with a HEK293 serum-free
suspension system, Homology's commercial scale process and platform gives the Company the ability to produce large scale volumes to support its gene therapy and editing programs, and can be further leveraged to target
larger disease areas.